scispace - formally typeset
K

Karen R. Cleary

Researcher at University of Texas MD Anderson Cancer Center

Publications -  158
Citations -  20952

Karen R. Cleary is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Adenocarcinoma & Metastasis. The author has an hindex of 67, co-authored 158 publications receiving 20453 citations. Previous affiliations of Karen R. Cleary include University of Texas Health Science Center at Houston & University of Florida.

Papers
More filters
Journal Article

Human colonic sulfomucin identified by a specific monoclonal antibody

TL;DR: Sulfomucin reactivity with mAb 91.9H, as determined by solid-phase-binding inhibition and by dot blot assays, was significantly reduced by chemical desulfation of sulfomucins with anhydrous hydrochloric acid, suggesting that sulfate groups served as a portion of the immunochemical determinant for this antibody.
Journal ArticleDOI

The Association of Shiga Toxin and Other Cytotoxins with the Neurologic Manifestations of Shigellosis

TL;DR: Shiga toxin production is not essential for the development of neurologic manifestations of shigellosis; other toxic products may play a role.
Journal ArticleDOI

Chemoradiation for adenocarcinoma of the anus.

TL;DR: Patients with localized adenocarcinoma of the anus treated with definitive chemoradiation had high rates of pelvic failure and distant metastasis compared with comparably staged patients with epidermoid histologic features treated similarly, and are recommended for preoperative cheMoradiation followed by abdominoperineal resection to maximize pelvic disease control and consideration of adjuvant chemotherapy to address the problem of micrometastatic disease.
Journal ArticleDOI

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head: Survival and pattern of failure analysis

TL;DR: Preoperative chemoradiation, PD, and electron-beam intraoperative radiation therapy for adenocarcinoma of the pancreatic head have resulted in improved local-regional tumor control, with distant metastatic disease becoming the predominant site of tumor recurrence.